Advertise on podcast: The HemOnc Pulse

In this Editor’s Special episode of The HemOnc Pulse, MD Anderson Cancer Center’s Naval Daver, MD, and Naveen Pemmaraju, MD, discuss MDS/MPN overlap conditions and research examining combination therapy with ruxolitinib and azacitidine (AZA), including its potential to improve disease response, symptom control, and outcomes.

How can bispecific antibodies be safely delivered outside the hospital? Rahul Banerjee, MD and Ajay Nooka, MD discuss outpatient step-up dosing, prophylactic tocilizumab, CRS management, and practical tips for implementing bispecific therapy in academic and community practice.

In this episode of HemOnc Pulse, host Dr. Rahul Banerjee of Fred Hutchinson Cancer Center sits down with Dr. Gary Simmons, a hematologist-oncologist at Virginia Oncology Associates, to explore the evolving role of community-based cellular therapy programs and the future of patient access to innovative treatments.

Learn how new approaches in allogeneic transplants, from PTCy to innovative regimens, are helping reduce GVHD and improve patient outcomes with special guest Sagar S. Patel, MD of University of Utah Health.

In this Editor’s Special Episode of The HemOncPulse, a conversation with Nicholas Richardson, DO, MPH, vice president of clinical development at Precision for Medicine, focuses on the evolving regulatory role of measurable residual disease in multiple myeloma clinical trials. The discussion is designed to contextualize recent FDA draft guidance for a broad clinical and research audience.

In this episode of TheHemOnc Pulse, Rahul Banerjee, MD, speaks with Francine Foss, MD, professor of medicine and dermatology at Yale School of Medicine, about the evolving landscape of T-cell lymphomas. Dr Foss discusses the unique challenges of studying and treating rare diseases such as cutaneous T-cell lymphoma and explains why real-world data are essential to closing evidence gaps. The conversation highlights the role of collaborative registries in tracking treatment patterns, outcomes, and access to care across community and academic settings. Dr Foss also shares how both clinicians and patients can participate in these efforts to strengthen research, inform future clinical trials, and improve outcomes for patients with T-cell lymphomas.

This Editor’s Special Episode of The HemOnc Pulse features Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discussing treatment strategies for relapsed/refractory multiple myeloma and where selinexor-based regimens fit in today’s evolving landscape. Drawing from real-world cases, Dr. Richardson explores care for patients before CAR T, after CAR T relapse, and in between—highlighting how selinexor can be used flexibly across multiple lines, including as a bridge to future immunotherapies. The conversation emphasizes individualized, dynamic treatment planning to balance disease control, tolerability, and long-term goals in an increasingly complex era of myeloma care.

Dr. Eunice Wang joins host Rahul Banerjee, MD, for a clinician-focused discussion on AML, treatment complexity, and real-world leukemia management in today’s evolving therapeutic landscape.

In this episode of The HemOnc Pulse, host Melissa speaks with Omar Nadeem, MD, Senior Physician at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, about emerging genomic insights in smoldering multiple myeloma. The discussion focuses on recent research showing how molecular profiling can improve understanding of disease progression and refine risk stratification beyond traditional clinical models. Dr. Nadeem highlights how genomic data may help distinguish patients with smoldering myeloma who are at higher risk of progression from those likely to remain stable, offering the potential to guide more personalized treatment decisions. The conversation also explores the evolving landscape of precursor plasma cell disorders and the role of immunotherapy, including CAR T-cell therapy, in clinical management.

Dr. Rahul Banerjee interviews Dr. Ajay Major on patient-reported outcomes, toxicity reporting, and patient engagement in blood cancer clinical trials.

Dr. Hobbs joins the podcast to discuss the latest advances in myeloproliferative neoplasms (MPNs), including ropeginterferon and the VERIFY trial of rusfertide in polycythemia vera. He highlights key efficacy and safety data, unmet needs in essential thrombocythemia and myelofibrosis, and the next wave of clinical trials to watch.

Host Rahul Banerjee, MD, speaks with Drs. Frederik Schjesvold and Frida Askeland on myeloma trial results, relevance in the IMROZ/CEPHEUS era, and advances in treating elderly, frail patients.

MD Anderson fellows discuss AML, MRD endpoints, and evolving trial strategies in a dynamic grand rounds–style presentation.

William Wierda, MD, PhD of the University of Texas MD Anderson discusses advances in chronic lymphocytic leukemia care, from targeted therapies and resistance to immune dysfunction and prevention with Blood Cancers Today Managing Editor, Nichole Tucker.

In this Editor’s Special Episode of The HemOnc Pulse, Dr. Hira Mian of McMaster University shares expert insights on the evolving treatment landscape for multiple myeloma. From optimizing selinexor use, to understanding long-term MonumenTAL-1 data with talquetamab, to the promise of emerging trispecific antibodies, Dr. Mian highlights the biggest shifts shaping care today.